| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 07/03/2002 | CN1357050A Adenoviral vectors for treating disease |
| 07/03/2002 | CN1357049A Receptor based antagonists and mehtods of making and using |
| 07/03/2002 | CN1357048A Enhanced prodrug activation |
| 07/03/2002 | CN1357006A Mage-A1 peptides presented by HLA class II molecules |
| 07/03/2002 | CN1357003A 类固醇衍生物 Steroid derivatives |
| 07/03/2002 | CN1357000A Water soluble prodrugs of hindered alcohols or phenols |
| 07/03/2002 | CN1356995A Substituted benzimidazole |
| 07/03/2002 | CN1356991A Quinoline and quinoxaline compounds as PDGF-R and/or LCD tyrosine kinase inhibitors |
| 07/03/2002 | CN1356990A Bicyclic heterocycles, medicaments contg. these compounds, their use and methods for prodn. thereof |
| 07/03/2002 | CN1356986A Spiroimidazolidine derivatives, their prepn. their use and pharmaceutical prepns. comprising them |
| 07/03/2002 | CN1356913A Vitronectic receptor antagonist pharmaceuticals |
| 07/03/2002 | CN1356910A Model membrane systems |
| 07/03/2002 | CN1356909A Treatment of hemoatological malignancies associated with circulating tumor cells using chimeric anti-CD20 antibody |
| 07/03/2002 | CN1356892A Use of biodegradable microspheres for delivery of anticancer for treatment of glioblastoma |
| 07/03/2002 | CN1356872A 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy |
| 07/03/2002 | CN1356341A Anti-idiotype microantibody and its preparing process and application |
| 07/03/2002 | CN1356125A Medicine for treating tumor |
| 07/03/2002 | CN1356113A Process for preparing Chinese medicine to treat cardiovascular and cerebrovascular diseases |
| 07/03/2002 | CN1356107A Freezing-dried injection powder 'Katisu' and its preparing process |
| 07/03/2002 | CN1356061A Multi-purpose high-function solution composition, its preparing process and its usage as non-specific immanopotentiator |
| 07/02/2002 | US6414148 Produce antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals |
| 07/02/2002 | US6414130 Polypeptides binds to extracellular domain, glycosylated polypeptide or monoclonal antibody; antitumor agents |
| 07/02/2002 | US6414113 Amino acid sequence of peptide; for purifying and detecting bone marrow stromal cell antigen-1 |
| 07/02/2002 | US6414034 Anticancer agents |
| 07/02/2002 | US6414025 Rheumatic disorders; antiinflammatory agents; autoimmune diseases |
| 07/02/2002 | US6414015 Antiproliferative agents |
| 07/02/2002 | US6414014 Calibration dosage; side effect reduction |
| 07/02/2002 | US6414013 Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention |
| 07/02/2002 | US6413996 Diaminocyclobutene-3,4-dione derivatives, their preparation and use |
| 07/02/2002 | US6413974 Inhibitors of cyclin dependent kinases, particularly cdk-2; preventing apoptosis in neuronal cells; antineoplastic agents; neuronal injury and degeneration; cerebrovascular disease |
| 07/02/2002 | US6413971 Antiproliferative, -carcinogenic, -tumor and -diabetic agents; binding to or modulating the human kinase insert-domain-containing receptor (kdr) or the murine fetal liver kinase 1 (flk-1) receptor; vasculogenesis; angiogenesis |
| 07/02/2002 | US6413964 14-amino-14-(1-methyl-1h-imidazol-5-yl)-8-oxa-2-thia-1,18 -diazatetracyclo(16.2.2.1(3,7).1(9,13))tetracosa-3(24),4,6, 9(23),10,12-hexaene-10-carbonitrile 2,2-dioxide, for example; use in radiotherapy, chemotherapy as sensitizer |
| 07/02/2002 | US6413963 Alpha, beta-integrin inhibitors used in the treatment of multiple sclerosis, atherosclerosis, asthma and inflammatory bowel disease |
| 07/02/2002 | US6413958 For treatment/prevention of infection of herpes simplex virus, varicella zoster virus, human cytomegalovirus, or epstein-barr virus; enzyme inhibitors |
| 07/02/2002 | US6413957 Methods of inhibiting cell proliferation using indeno [1,2-c]pyrazol-4-ones |
| 07/02/2002 | US6413955 1,8-naphthyridines or 5-thio-1,8-naphthyridines or 5-oxo-1,8-naphthyridines; bone resorption, osteoporosis, vascular rest-enosis, diabetic retinopathy, macular degeneration, angio-genesis, atherosclerosis, inflammatory arthritis, cancer |
| 07/02/2002 | US6413954 Certain substituted caprolactam carbonates and ethers, pharmaceutical compositions containing them and their use in treating tumors |
| 07/02/2002 | US6413953 Amine(chloro)trihydroxo(2-methylpyridine)platinum(iv); water solubility; single or combined therapy with gemcitabine, etoposide or taxol or radiotherapy; diminished side effects; improved bioavailability; anticancer agent; ovarian cancer |
| 07/02/2002 | US6413939 Inducible phosphofructokinase and the Warburg effect |
| 07/02/2002 | US6413936 Glycomimetics as selectin antagonists and pharmaceuticals having antiinflammatory activity |
| 07/02/2002 | US6413932 Tek antagonists comprising soluble tek extracellular binding domain |
| 07/02/2002 | US6413770 NL4 tie ligand homologue nucleic acid |
| 07/02/2002 | US6413756 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 07/02/2002 | US6413755 Human checkpoint kinase, HCDS1, compositions and methods |
| 07/02/2002 | US6413735 Method of screening for a modulator of angiogenesis |
| 07/02/2002 | US6413731 Methods of screening for compounds which bind to a human SNORF36A receptor |
| 07/02/2002 | US6413533 Administering antiestrogen |
| 07/02/2002 | US6413507 Modified polyether |
| 07/02/2002 | CA2184908C Human osteoclast-derived cathepsin |
| 07/02/2002 | CA2124315C Nitroaniline derivatives and their use as antitumor agents |
| 07/02/2002 | CA2123696C Antitumor vaccines |
| 07/02/2002 | CA2006372C Process for preparing isothiocyanato functionalized metal complexes |
| 07/02/2002 | CA1341373C Macrocyclic bifunctional chelants, complexes thereof and their antibody conjugates |
| 06/27/2002 | WO2002050304A2 Oncolytic virus |
| 06/27/2002 | WO2002050289A1 Methods for the production of multimeric proteins, and related compositions |
| 06/27/2002 | WO2002050286A2 Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof |
| 06/27/2002 | WO2002050284A2 Oxidoreductases |
| 06/27/2002 | WO2002050279A2 Nucleic acid-associated proteins |
| 06/27/2002 | WO2002050270A1 Novel tissue-specific secretory polypeptide and dna thereof |
| 06/27/2002 | WO2002050255A2 Isolated human dehydrogenases, nucleic acid molecules encoding them, and uses thereof |
| 06/27/2002 | WO2002050122A2 Means for the diagnosis and therapy of ctcl |
| 06/27/2002 | WO2002050120A2 High affinity antibodies |
| 06/27/2002 | WO2002050105A1 Novel compounds |
| 06/27/2002 | WO2002050102A2 Inhibitors of the e2f-1/cyclin interaction for cancer therapy |
| 06/27/2002 | WO2002050101A1 Retinoblastoma-binding protein |
| 06/27/2002 | WO2002050079A1 Cyclin-dependent kinase (cdk) and glycolene synthase kinase-3 (gsk-3) inhibitors |
| 06/27/2002 | WO2002050073A1 Pyrazolo[3,4-c]pyridines as gsk-3 inhibitors |
| 06/27/2002 | WO2002050071A1 Thiazolyl inhibitors of tec family tyrosine kinases |
| 06/27/2002 | WO2002050066A2 Pyrazole compounds useful as protein kinase inhibitors |
| 06/27/2002 | WO2002050065A2 Pyrazole compounds useful as protein kinase inhibitors |
| 06/27/2002 | WO2002050058A1 Crystal forms of 6-[(4-chloro-phenyl) -hydroxy-(-3-methyl- 3h-imidaol-4-yl) -methyl] -4-(3-ethynyl-phenyl) -1-methyl-1h- quinolin-2-one, 2,3- dihydroxybutanedioate salts and method of production |
| 06/27/2002 | WO2002050043A1 Quinazoline derivatives, medicaments containing said compounds, their utilization and method for the production thereof |
| 06/27/2002 | WO2002050041A1 Dihydroindole and tetrahydroquinoline derivatives |
| 06/27/2002 | WO2002050039A1 Urea and urethane derivatives as integrin inhibitors |
| 06/27/2002 | WO2002050033A1 Benzo(f) isoindol derivatives and their use as ep4 receptor ligands |
| 06/27/2002 | WO2002050032A1 Naphthalene derivatives which bind to the ep4 receptor |
| 06/27/2002 | WO2002050031A1 Indole derivatives |
| 06/27/2002 | WO2002050028A2 Substituted benzoindoles as spla2 inhibitors |
| 06/27/2002 | WO2002050023A2 Synthesis of pancrastistatin |
| 06/27/2002 | WO2002050019A2 Diamines as modulators of chemokine receptor activity |
| 06/27/2002 | WO2002050007A2 Substituted stilbenes, their reactions and anticancer activity |
| 06/27/2002 | WO2002049654A1 Shark meat extract |
| 06/27/2002 | WO2002049651A1 Pharmaceutical formulation containing pyrazolo[4,3-d]pyrimidines and antithrombotic agents, calcium-antagonists, prostaglandins or prostaglandin derivatives |
| 06/27/2002 | WO2002049650A2 Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives |
| 06/27/2002 | WO2002049649A2 Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives (2) |
| 06/27/2002 | WO2002049634A2 Dissociated glucocorticoid receptor antagonists for the treatment of clucocorticoid associated side-effect |
| 06/27/2002 | WO2002049577A2 Analogues of thiocoraline and be-22179 |
| 06/27/2002 | WO2002049501A2 Local regional chemotherapy and radiotherapy using in situ hydrogel |
| 06/27/2002 | WO2002030879A3 Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors |
| 06/27/2002 | WO2002030393A3 Polymeric delivery formulations of leuprolide with improved efficacy |
| 06/27/2002 | WO2002030353A3 NF-λB INHIBITORS |
| 06/27/2002 | WO2002026935A3 TGF-β INHIBITORS AND METHODS |
| 06/27/2002 | WO2002026748A3 Metal complexes for use in medical and therapeutic applications |
| 06/27/2002 | WO2002022602A3 Triazole compounds useful as protein kinase inhibitors |
| 06/27/2002 | WO2002022592A3 Substituted urea neuropeptide y y5 receptor antagonists |
| 06/27/2002 | WO2002020822A3 Biopanning and rapid analysis of selective interactive ligands (brasil) |
| 06/27/2002 | WO2002020566A3 NOVEL MMP-2 DERIVATIVES FOR USE AS INHIBITORS OF INTEGRIN αVβ¿3? |
| 06/27/2002 | WO2002015881A3 Use of a porous carrier |
| 06/27/2002 | WO2002008231A3 Biologically active macrolides, compositions, and uses thereof |
| 06/27/2002 | WO2001097825A3 High molecular weight extracts of convolvulus arvensis (field bindweed) and polygonum convolvulus (wild buckwheat) |